Protagonist Therapeutics, Inc.
PTGX
$46.28
$0.481.05%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 170.64M | 4.68M | 4.17M | 254.95M | 60.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 170.64M | 4.68M | 4.17M | 254.95M | 60.00M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 170.64M | 4.68M | 4.17M | 254.95M | 60.00M |
| SG&A Expenses | 8.95M | 10.16M | 9.44M | 14.91M | 8.05M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.86M | 46.13M | 42.96M | 48.64M | 36.95M |
| Operating Income | 126.78M | -41.45M | -38.79M | 206.31M | 23.05M |
| Income Before Tax | 133.66M | -33.63M | -31.29M | 210.67M | 27.34M |
| Income Tax Expenses | 1.99M | -420.00K | -676.00K | 3.33M | -- |
| Earnings from Continuing Operations | 131.67M | -33.21M | -30.62M | 207.34M | 27.34M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 131.67M | -33.21M | -30.62M | 207.34M | 27.34M |
| EBIT | 126.78M | -41.45M | -38.79M | 206.31M | 23.05M |
| EBITDA | 126.90M | -41.22M | -38.55M | 206.55M | 23.30M |
| EPS Basic | 2.11 | -0.54 | -0.50 | 3.41 | 0.45 |
| Normalized Basic EPS | 1.34 | -0.34 | -0.32 | 2.16 | 0.28 |
| EPS Diluted | 1.99 | -0.54 | -0.50 | 3.26 | 0.44 |
| Normalized Diluted EPS | 1.26 | -0.34 | -0.32 | 2.07 | 0.28 |
| Average Basic Shares Outstanding | 62.33M | 61.77M | 61.31M | 60.86M | 60.39M |
| Average Diluted Shares Outstanding | 66.41M | 61.77M | 61.31M | 63.60M | 61.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |